Check out the latest story in Immunity from #RodriguezLab on tumor expressed Jagged2 hijacking Notch1/2 signaling in mΦ to drive immune evasion in NSCLC
j mandula Darwin Chang Tim Shaw 🇺🇸..🇹🇼..🇺🇸 Xiaoqing Yu Jose Conejo-Garcia Moffitt Research Moffitt Cancer Center
sciencedirect.com/science/articl…

Countdown to #AUA24 ; looking forward to the
AUA-IBCG Bladder Cancer Forum
Sunday, May 5, 2 - 5 pm

Amer. Urol. Assn. IBCG Janet Kukreja Amanda Myers Bladder Cancer Advocacy Network Andrea Necchi Petros Grivas Roger Li Karima Oualla, MD,MSc Shilpa Gupta Stephen B. Williams, MD, MBA, MS, FACHE Prof Param Mariappan

Trial is open and we look for more sites! Appreciate support to help pts with UTUC! ECOG-ACRIN Cancer Research Group Jean Hoffman-Censits SWOG Cancer Research Network Alliance for Clinical Trials in Oncology NRG Oncology Sia Daneshmand, M.D. Thomas Flaig Joshua Meeks Jonathan Rosenberg MD Matt Milowsky Roger Li Dr. John Sfakianos Sarah P. Psutka MD MS Ashish M. Kamat, MD, MBBS Yousef Zakharia Kriti Mittal, MD

Our team effort with Xiaofei (Sophia) Song and Roger Li integrates imaging and transcriptomic from GeoMx, highlighting the sweet ‘spot’ at the sub-cellular level. Thrilled to have many people stopped by, including the joe.beechem NanoString

#spatialOmics
#MoffittAACR24 AACR

Most oncology drugs granted accelerated approval did not demonstrate OS benefit
or improve QOL within 5 years of approval

Need better correlation of surrogate endpoints with what actually matters to patients

jamanetwork.com/journals/jama/… JAMA Oncology IBCG #EAU24 #AACR24

What a start at #EAU24 - OS Update of CheckMate274 Adjuvant Nivolumab demonstrates OS benefit for high-risk MIBC, especially in PD-L1+ population! (HR 0.56) Matt Galsky

But: Why did adjuvant Nivo perform better than Pembro (AMBASSADOR did not demonstrate OS benefit ASCO

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

Congrats to Dr. Bishoy M. Faltas on another major achievement.
eipm.weill.cornell.edu/news/dr-bishoy…
Bladder Cancer Advocacy Network UroToday.com Uromigos

Just released! Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG)

ascopubs.org/doi/pdf/10.120…
Journal of Clinical Oncology IBCG Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer IBCG Matt Galsky Join us for this focused Society for Immunotherapy of Cancer webinar where we will be discussing highlights from our guidance paper U.S. FDA IBCG Matt Galsky Andrea Apolo, M.D. Shilpa Gupta Sarah P. Psutka MD MS UroToday.com Roger Li

x.com/urodocash/stat…

It was true pleasure to share our ARID1A and CXCL13 work at 2024 AUA-JHU Bladder Cancer Symposium: Integrating biomarkers into bladder cancer clinical trials. Thank you for the invitation David McConkey Matt Galsky Amer. Urol. Assn. Johns Hopkins Greenberg Bladder Cancer Institute MD Anderson Cancer Center

Fabulous talk by Dr. Koti at AUA-JHU bladder symposium ⁦Madhuri Koti⁩ ⁦Johns Hopkins Greenberg Bladder Cancer Institute⁩ ⁦⁦Amer. Urol. Assn.⁩

The first day at the Amer. Urol. Assn. JHU bladder cancer biomarkers session was a success Madhuri Koti, Sangeeta Goswami, MD,PhD, and Woonyoung Cho Johns Hopkins University showcased their latest research findings, concentrating on TLS, epigenetic factors, and markers for chemotherapy response 👏👏

Roger Li, MD from Moffitt Cancer Center discusses Integrating Liquid Biopsies in Clinical Trials during the AUA JHU Bladder Cancer Workshop Roger Li

New ESMO - Eur. Oncology guidlines for advanced bladder cancer Annals of Oncology. Enforumab Vedotin & pembro is the new standard of care. Platinum therapy is now 2nd line and eligibility less relevant. Gem/cis/nivo or maintenance avelumab for pts where EVP not available annalsofoncology.org/article/S0923-…

nature.com/articles/s4301… very interesting work showing role of APOBEC3C and D in restarting stalled replication forks. Highlighting diversity of roles with the APOBEC3 family.

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

For #TrialTuesday , .Matt Galsky Icahn School of Medicine at Mount Sinai leads Alliance for Clinical Trials in Oncology A032103 (MODERN) to test the role of DNA released from tumor cells into the blood in guiding the use of #immunotherapy after bladder removal for #bladdercancer treatment: bit.ly/Alliance-A0321… @bladdercancerus

Rashid K. Sayyid and Zach Klaassen explore recommendations from the Society for Immunotherapy of Cancer and the IBCG for designing clinical trials in high-risk #NMIBC . The consensus statement aims to guide investigators in late-phase clinical trial design > bit.ly/42P2Hts Ashish M. Kamat, MD, MBBS

A study from Roger Li and colleagues evaluated the benefits of neoadjuvant #pembrolizumab plus radical cystectomy for patients with #MIBC . Learn more: buff.ly/3UNByVE